NantKwest Tech Stack

NantKwest uses 8 technology products and services including TrackJs, Select2, SweetAlert2, and more. Explore NantKwest's tech stack below.

  • TrackJs
    Analytics
  • Select2
    Javascript Libraries
  • SweetAlert2
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • jQuery Mobile
    Mobile Frameworks
  • Yoast SEO
    Search Engines
  • Bootstrap
    UI Frameworks
  • Apache
    Web Servers

Media & News

NantKwest's Email Address Formats

NantKwest uses at least 4 format(s):
NantKwest Email FormatsExamplePercentage
first.last@nantkwest.comJohn.Doe@nantkwest.com
83%
lastf@nantkwest.comDoeJ@nantkwest.com
14%
first@nantkwest.comJohn@nantkwest.com
2%
flast@nantkwest.comJDoe@nantkwest.com
1%

Frequently Asked Questions

Where is NantKwest's headquarters located?

Minus sign iconPlus sign icon
NantKwest's main headquarters is located at 9920 Jefferson Blvd Culver City, CA 90232 US. The company has employees across 2 continents, including North AmericaEurope.

What is NantKwest's phone number?

Minus sign iconPlus sign icon
You can contact NantKwest's main corporate office by phone at +1-858-633-0300. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is NantKwest's stock symbol?

Minus sign iconPlus sign icon
NantKwest is a publicly traded company; the company's stock symbol is IBRX.

What is NantKwest's official website and social media links?

Minus sign iconPlus sign icon
NantKwest's official website is nantkwest.com and has social profiles on LinkedIn.

How much revenue does NantKwest generate?

Minus sign iconPlus sign icon
As of February 2024, NantKwest's annual revenue reached $35M.

What is NantKwest's SIC code NAICS code?

Minus sign iconPlus sign icon
NantKwest's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does NantKwest have currently?

Minus sign iconPlus sign icon
As of February 2024, NantKwest has approximately 40 employees across 2 continents, including North AmericaEurope. Key team members include Chief Medical Officer: A. N.Head Of Operations Project Management: C. W.Head, Pre-Clinical Development: M. P.. Explore NantKwest's employee directory with LeadIQ.

What industry does NantKwest belong to?

Minus sign iconPlus sign icon
NantKwest operates in the Biotechnology Research industry.

What technology does NantKwest use?

Minus sign iconPlus sign icon
NantKwest's tech stack includes TrackJsSelect2SweetAlert2jQueryjQuery MobileYoast SEOBootstrapApache.

What is NantKwest's email format?

Minus sign iconPlus sign icon
NantKwest's email format typically follows the pattern of first.last@nantkwest.com. Find more NantKwest email formats with LeadIQ.

How much funding has NantKwest raised to date?

Minus sign iconPlus sign icon
As of February 2024, NantKwest has raised $39M in funding. The last funding round occurred on Mar 26, 2019.
NantKwest

NantKwest

Biotechnology ResearchCalifornia, United States51-200 Employees

NantKwest (NASDAQ: NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Our “off-the-shelf” activated Natural Killer (NK) platform have the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease.

Our targeted therapeutic areas include: (1) cancer, focusing on bulky hematological cancers and solid tumors as well as cancer stem cells, (2) infectious diseases, including viral, fungal and bacterial infections, and (3) inflammatory diseases, ranging from rare inherited diseases to more prevalent autoimmune disorders.

Section iconCompany Overview

Headquarters
9920 Jefferson Blvd Culver City, CA 90232 US
Phone number
+1-858-633-0300
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
IBRX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $39M

    NantKwest has raised a total of $39M of funding over 3 rounds. Their latest funding round was raised on Mar 26, 2019.

  • $10M$50M

    NantKwest's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $39M

    NantKwest has raised a total of $39M of funding over 3 rounds. Their latest funding round was raised on Mar 26, 2019.

  • $10M$50M

    NantKwest's revenue is in the range of $10M$50M

© LeadIQ, Inc. All rights reserved.